» Articles » PMID: 37110416

Towards a Standardized Antimicrobial Susceptibility Testing Method for

Overview
Journal Microorganisms
Specialty Microbiology
Date 2023 Apr 28
PMID 37110416
Authors
Affiliations
Soon will be listed here.
Abstract

Conducting antimicrobial susceptibility testing (AST) in a comparable manner requires the availability of a standardized method. Organizations, such as the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST), provide standardized protocols for a range of fastidious bacteria but not for . We developed a broth microdilution method for testing in a standardized and harmonized way using a modified Friis broth devoid of antimicrobial or otherwise bacterial growth-inhibiting agents. The type strain DSM 25591 was chosen to establish the methodology. The antimicrobial agents of interest were doxycycline, enrofloxacin, erythromycin, florfenicol, gentamicin, marbofloxacin, tetracycline, tiamulin, tilmicosin, tulathromycin, and tylosin, tested by using commercial Sensititre microtiter plates. In addition, the suitability of the methodology was evaluated via variation of the individual ingredients of the modified Friis broth by either using different batches or choosing other distributors. Despite these alterations, the method provided reliable results. We obtained repeatable minimal inhibitory concentrations for all six tested field isolates and the type strain. With this newly proposed method, we aim to provide an improved AST method for diagnostic laboratories and monitoring purposes with better comparability between times and countries. In addition, this new method will allow for an improvement of targeted treatments using antimicrobial agents and thereby reduce the options for resistance development.

Citing Articles

Evaluation of a Method for Standardized Antimicrobial Susceptibility Testing with Field Isolates.

Kabisch L, Schink A, Hoeltig D, Verspohl J, Gyuranecz M, Spergser J Microorganisms. 2023; 11(12).

PMID: 38138024 PMC: 10746044. DOI: 10.3390/microorganisms11122881.

References
1.
Kobayashi H, Morozumi T, Munthali G, Mitani K, Ito N, Yamamoto K . Macrolide susceptibility of Mycoplasma hyorhinis isolated from piglets. Antimicrob Agents Chemother. 1996; 40(4):1030-2. PMC: 163254. DOI: 10.1128/AAC.40.4.1030. View

2.
Bunger M, Brunthaler R, Unterweger C, Loncaric I, Dippel M, Ruczizka U . Mycoplasma hyorhinis as a possible cause of fibrinopurulent meningitis in pigs? - a case series. Porcine Health Manag. 2020; 6(1):38. PMC: 7713030. DOI: 10.1186/s40813-020-00178-8. View

3.
Gardella R, Del Giudice R . Growth of Mycoplasma hyorhinis cultivar alpha on semisynthetic medium. Appl Environ Microbiol. 1995; 61(5):1976-9. PMC: 167459. DOI: 10.1128/aem.61.5.1976-1979.1995. View

4.
Li J, Wei Y, Wang J, Li Y, Shao G, Feng Z . Characterization of Mutations in DNA Gyrase and Topoisomerase IV in Field Strains and In Vitro Selected Quinolone-Resistant Mutants. Antibiotics (Basel). 2022; 11(4). PMC: 9024574. DOI: 10.3390/antibiotics11040494. View

5.
Kobayashi H, Nakajima H, Shimizu Y, Eguchi M, Hata E, Yamamoto K . Macrolides and lincomycin susceptibility of Mycoplasma hyorhinis and variable mutation of domain II and V in 23S ribosomal RNA. J Vet Med Sci. 2005; 67(8):795-800. DOI: 10.1292/jvms.67.795. View